Structural Biology meets Drug Discovery in this Cool Company

After an amazing day in Paris for Labiotech Refresh, we head back to Germany to meet Proteros. The company is working non-stop to provide drug candidates against some of the hottest targets in biotech.


proteros logo

City: Munich, Germany

Founded: 1999

Employees: 80+

Financial data: The company just announced a €157M ($167M) deal with MSD

Torsten Neuefeind

Torsten Neuefeind, CEO

Mission: Proteros’ expertise in structural biology has led the company to build a strong pipeline focused on oncology and neurology. Its drugs are directed at epigenetic targets, kinases, and G-protein-coupled receptors (GPCRs), three hot areas in the biotech industry.

Comment: The new deal with MSD comes as another great collaboration for Proteros on top of already established ones with top level players Janssen and Bayer. Unfortunately, the company keeps secret most details of these partnerships, so it’s difficult to evaluate its impact.


Featured image: Labiotech map


Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.